Skip to main content

A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction

Recruiting · Phase 3 · NCT06082037

Conditions: Lung Transplant Rejection

At a glance

Research payments reported, 2025
$1.5M
U.S. investigators named
30
Sites paid
34
Planned or actual enrollment
180

About the trial

Sponsor
Sanofi (with Meiji Seika Pharma Co., Ltd.)
Tested
Belumosudil (drug), Azithromycin (drug), Placebo (drug)
Dates
Started 2023-10-10; completion 2030-10-01
Results posted
Not yet

This double-blind, randomized, placebo-controlled, multinational, multicenter, parallel-group, Phase 3, 2-arm, study will investigate the efficacy and safety of belumosudil compared with placebo, both administered on top of azithromycin and standard-of-care regimen of immunosuppression in male or female participants at least 1 year after bilateral lung transplant, who are at least 18 years of age and who have evidence of progressive CLAD despite azithromycin therapy. Study details include: The study duration will be up to 31 weeks for participants not entering the open-label extension (OLE) period and up to 57 weeks for participants entering the OLE period but not the long-term OLE. The t…

From ClinicalTrials.gov, last updated 2026-10-28. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Sanofi US Services Inc. reported $1.5M in research payments for this study in 2025 (228 payments).

Products named: Rezurock

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.